Drug Update · Dermatology

FDA Approves roflumilast (ZORYVE) for Plaque Psoriasis: 71.9% Intertriginous‑IGA Success at Week 8

September 03, 2026

Indication

Topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 2 years of age and older [1]

Approved formulation for plaque psoriasis

ZORYVE cream, 0.3% applied once daily to affected areas [1][2]

Pediatric age (plaque psoriasis)

Approved in pediatric patients 2 years of age and older [1]

Intertriginous‑IGA success (Week 8)

71.9% roflumilast 0.3% vs 20.5% vehicle [5]

IGA or body‑IGA success (Week 8)

Relative risk 5.07; 95% CI 3.55-7.23 (roflumilast 0.3% vs vehicle) [5]

Clinical Perspective

Dermatologists and pediatric clinicians treating children and adults with plaque psoriasis—including disease in intertriginous areas and patients aged 2 to 5 years—should be aware that topical roflumilast (ZORYVE) 0.3% is labeled for this indication ^[1]^[2]. Randomized trials and pooled analyses support greater IGA‑type and PASI responses, including intertriginous‑IGA success at Week 8, for once‑daily roflumilast 0.3% versus vehicle ^[5]^[4]. How roflumilast cream compares directly with conventional topical corticosteroids or other active topical comparators for efficacy and safety in intertriginous and facial disease in children 2 to 5 years of age remains an open question?

Dr. Divya Agarwal, MBBS, MD (Dermatology, Venereology & Leprosy) · Dermatology

ZORYVE (roflumilast) cream, 0.3%, is indicated for the topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 2 years of age and older per recent labeling revised 6/2026 ^[1]^[2]. Randomized controlled trials and pooled analyses reported higher Investigator’s Global Assessment (IGA)–type success rates and specific intertriginous‑IGA success at Week 8 with topical roflumilast versus vehicle in adults and children ^[5]^[4].

Clinical Context

Roflumilast is a phosphodiesterase 4 (PDE4) inhibitor formulated as topical creams and foams marketed by Arcutis Biotherapeutics, Inc. and described in current U.S. prescribing information ^[1]^[2]^[3]. The updated labeling lists ZORYVE cream, 0.3%, for plaque psoriasis inclusive of intertriginous areas in patients 2 years and older; other ZORYVE strengths (0.15% and 0.05%) have atopic dermatitis indications in defined pediatric age bands ^[1]^[2]. Conventional topical approaches to plaque psoriasis frequently include glucocorticoids and vitamin D derivatives, which are referenced in contemporary reviews of topical management strategies ^[7]. The clinical literature includes multicenter randomized, double‑blind, vehicle‑controlled trials that form the evidence base for topical roflumilast in plaque psoriasis and pooled analyses summarizing efficacy versus vehicle ^[4]^[5].

Key Findings

A systematic review and meta‑analysis of randomized controlled trials found that at Week 8 the achievement of IGA or body‑IGA success (clear or almost clear plus ≥2‑grade improvement) was higher with topical roflumilast 0.3% than with vehicle (relative risk [RR] 5.07; 95% CI 3.55-7.23) ^[5].
The same meta‑analysis reported higher PASI‑50 (RR 2.73; 95% CI 2.27-3.29), PASI‑75 (RR 4.48; 95% CI 2.26-8.89), and PASI‑90 (RR 5.61; 95% CI 2.57-12.25) outcomes at Week 8 for roflumilast 0.3% versus vehicle ^[5].
For intertriginous disease specifically, topical roflumilast 0.3% once daily achieved intertriginous‑IGA success of 71.9% versus 20.5% with vehicle at Week 8 in pooled trial data reported in the meta‑analysis ^[5].
Clinicians should consult current prescribing information for full dosing guidance.
The NDA/labeling package and FDA clinical review identify two key multicenter, randomized, double‑blind, vehicle‑controlled trials in plaque psoriasis (DERMIS‑1 and DERMIS‑2) that contributed to the evidence base summarized in the label and review ^[4]^[1].

Safety & Tolerability

The prescribing information lists the most common adverse reactions (reported in ≥1% of subjects) for plaque psoriasis as diarrhea, headache, insomnia, nausea, application site pain, upper respiratory tract infection, and urinary tract infection ^[1]^[2].
Clinical trial publications and the FDA clinical review described adverse events in pediatric maximal‑use pharmacokinetic/safety studies as generally mild, with few treatment‑related events reported under maximal‑use conditions ^[4]^[6].
A pooled analysis reported a higher overall incidence of adverse events in roflumilast versus vehicle groups but found no difference in treatment‑related adverse events, serious adverse events, or adverse events leading to study discontinuation in the trials analyzed ^[5].

Study Design

The clinical evidence base cited in the label and FDA review includes multicenter, randomized, double‑blind, vehicle‑controlled trials (DERMIS‑1 and DERMIS‑2) that enrolled subjects with mild to severe plaque psoriasis and evaluated once‑daily topical roflumilast 0.3% versus vehicle with Week 8 efficacy endpoints cited in the label and review ^[4]^[1]. A systematic review and meta‑analysis pooled four randomized controlled trials totaling 1,403 patients to report Week 8 IGA/body‑IGA and PASI outcomes ^[5]. Pediatric maximal‑use pharmacokinetic and safety studies in younger age groups were conducted under PREA commitments and summarized in the FDA clinical review ^[4]^[6].

FAQ

Q1 What is roflumilast (ZORYVE) approved for?

Roflumilast cream, 0.3%, is approved for the topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 2 years of age and older. Separate ZORYVE strengths (0.15% and 0.05%) have approved atopic dermatitis indications in specified pediatric age groups as described in the prescribing information.

Q2 How does roflumilast work?

Roflumilast is a phosphodiesterase 4 (PDE4) inhibitor; inhibition of PDE4 and its active metabolite roflumilast N‑oxide leads to accumulation of intracellular cyclic AMP. The prescribing information and product descriptions identify PDE4 inhibition as the pharmacologic category for topical roflumilast formulations.

Q3 What is the recommended dose of roflumilast for plaque psoriasis?

For plaque psoriasis, the prescribing information directs use of ZORYVE cream, 0.3%, applied once daily to affected areas. The label specifies topical use only and cautions against ophthalmic, oral, or intravaginal application; consult product labeling for full administration instructions and age‑specific information.

Q4 What are the most common side effects?

The most common adverse reactions reported for plaque psoriasis in the prescribing information (≥1% of subjects) include diarrhea, headache, insomnia, nausea, application site pain, upper respiratory tract infection, and urinary tract infection. Trial summaries and pooled analyses reported a higher overall incidence of adverse events with roflumilast versus vehicle but did not find differences in treatment‑related adverse events, serious adverse events, or adverse events leading to discontinuation in the analyzed trials.

Clinicians should consult current prescribing information for complete dosing guidance.

FDA Approves roflumilast (ZORYVE) for Plaque Psoriasis: 71.9% Intertriginous‑IGA Success at Week 8

Direct Clinical Takeaway & Evidence Summary

FDA Approves roflumilast (ZORYVE) for Plaque Psoriasis: 71.9% Intertriginous‑IGA Success at Week 8

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Dermatology in your inbox.

Related Clinical Updates

FDA Approves Roflumilast (ZORYVE) Cream for Plaque Psoriasis: IGA Success 41.5% (DERMIS-1)

Deucravacitinib (SOTYKTU): Clinical Deep‑Dive in Plaque Psoriasis

Dupilumab Label Updates 2025: Atopic Dermatitis Indication and Dosing

Verified HCP Portal